Nicox (FRA:NXOA) 3-Year Revenue Growth Rate : -32.30% (As of Jun. 2024)

View and export this data going back to . Start your Free Trial

What is Nicox 3-Year Revenue Growth Rate?

Nicox's Revenue per Share for the six months ended in Jun. 2024 was €0.10.

During the past 12 months, Nicox's average Revenue per Share Growth Rate was 56.30% per year. During the past 3 years, the average Revenue per Share Growth Rate was -32.30% per year. During the past 5 years, the average Revenue per Share Growth Rate was -11.80% per year. During the past 10 years, the average Revenue per Share Growth Rate was 27.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of Nicox was 548.70% per year. The lowest was -82.10% per year. And the median was -8.50% per year.

Competitive Comparison of Nicox's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, Nicox's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nicox's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nicox's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Nicox's 3-Year Revenue Growth Rate falls into.

Nicox 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Nicox (FRA:NXOA) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Nicox 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Nicox's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Nicox Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nicox SA (FRA:NXOA) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

NICXF:USA 0RCQ:UK ALCOX:France NXOA:Germany

Address

Rue Evariste Galois, Emerald Square, Batiment C, Sundesk Sophia Antipolis, Biot, FRA, 06410

Website

https://www.nicox.com

Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Its lead program in clinical development is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company also has a preclinical research program on NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, with Glaukos. Its first product, VYZULTA in glaucoma, licensed exclusively worldwide to Bausch + Lomb, is available commercially in the U.S. and over 15 other territories. Nicox generates revenue from ZERVIATE in allergic conjunctivitis, licensed in multiple geographies.

Nicox Headlines

No Headlines